No Data
Morgan Stanley Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $30
Cautious Hold on Apellis Pharmaceuticals Amid Competitive Landscape and Promising Empaveli Prospects
Jefferies Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $57
Scotiabank Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $30
William Blair Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating
Buy Rating for Apellis Pharmaceuticals Driven by Empaveli's Market Potential and Efficacy in C3G Treatment
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
been hot today but that's getting into buying range for me..... EBS middle size company that got a new CEO last year completely changed things around since for EBS. take a look at who owns EBS and how much together. this small float is trading around 50% since half or more is already bought up by insiders or tutes